Loading stock data…
$55.95-0.68 (-1.20%)
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally.
BioMarin Pharmaceutical Inc. in the Healthcare sector is trading at $55.95 with a market capitalization of $11.9B. Wall Street consensus targets $91.56 (27 analysts), implying a +63.6% move over the next 12 months. The stock is currently 21% below its 52-week high of $70.98, remaining 4.3% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $989.71M↑ | $766.21M↓ | $874.57M↑ | $776.13M↓ | $825.41M |
| Gross Profit | $786.91M↑ | $571.21M↓ | $598.86M↓ | $636.05M↓ | $675.32M |
| Operating Income | $110.97M↓ | $129.63M↑ | -$44.60M↑ | -$46.68M↓ | $276.87M |
| Net Income | $44.76M↓ | $105.53M↑ | -$46.57M↓ | -$30.74M↓ | $240.53M |
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Paci...